Ticker > Company >

Caplin Point Labs. share price

Caplin Point Laboratories Ltd.

  2.78 L   1.65 K   256 NSE: CAPLIPOINT BSE: 524742 SECTOR: Pharmaceuticals & Drugs

2542.35
+21.80 (0.86%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 2558.95

Today's Low

₹ 2507

52 Week High

₹ 2700

52 Week Low

₹ 1502.45

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

19324.83 Cr.

Enterprise Value

19110.12 Cr.

No. of Shares

7.6 Cr.

P/E

46.04

P/B

8.9

Face Value

₹ 2

Div. Yield

0.16 %

Book Value (TTM)

₹  285.6

CASH

214.71 Cr.

DEBT

0 Cr.

Promoter Holding

70.57 %

EPS (TTM)

₹  55.22

Sales Growth

20.37%

ROE

22.21 %

ROCE

28.58%

Profit Growth

19.66 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 22Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year20.37%
3 Year12.53%
5 Year7.35%

Profit Growth

1 Year19.66%
3 Year21.8%
5 Year11.43%

ROE%

1 Year22.21%
3 Year22.62%
5 Year22.79%

ROCE %

1 Year28.58%
3 Year28.61%
5 Year29.28%

Debt/Equity

0

Price to Cash Flow

98.66

Interest Cover Ratio

3681.5833

CFO/PAT (5 Yr. Avg.)

0.823587669363161

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 70.57 0.00
Mar 2026 70.57 0.00
Dec 2025 70.57 0.00
Sep 2025 70.57 0.00
Jun 2025 70.56 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 21.8025882507694% for the Past 3 years.
  • Company has been maintaining healthy ROE of 22.6237333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.6106333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 3681.5833.
  • The Company has been maintaining an effective average operating margins of 43.3047285805463% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 3.77380000000001 days.
  • Company has a healthy liquidity position with current ratio of 8.2693.
  • The company has a high promoter holding of 70.57%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 55.5600699571412.

 Limitations

  • The company has shown a poor revenue growth of 12.5269592363449% for the Past 3 years.
  • The company is trading at a high PE of 46.04.
  • The company is trading at a high EV/EBITDA of 33.9521.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 182.57 175.18 189.22 191.36 202.95
Total Expenditure 95.96 99.33 97.5 107.77 108.54
Operating Profit 86.61 75.85 91.72 83.59 94.41
Other Income 32.03 59.22 31.73 61.08 62.79
Interest 0.04 0.05 0.07 0.05 0.05
Depreciation 6.14 6.02 6.37 6.9 6.56
Exceptional Items 0 0 0 0 0
Profit Before Tax 112.46 129 117.01 137.72 150.59
Tax 26.57 26.41 29.73 28.22 30.21
Profit After Tax 85.89 102.59 87.28 109.5 120.38
Adjusted EPS (Rs) 11.3 13.5 11.48 14.41 15.84

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 482.68 528.06 528.61 625.09 752.41
Total Expenditure 273.14 308.58 309.23 338.01 420.44
Operating Profit 209.54 219.48 219.38 287.08 331.97
Other Income 23.01 56.69 99.54 105.84 134.59
Interest 0.17 0.09 0.12 0.1 0.12
Depreciation 22.44 25.77 25.65 27.08 24.77
Exceptional Items 0 0 0 0 0
Profit Before Tax 209.94 250.31 293.15 365.74 441.67
Tax 53.71 62.44 58.89 82.03 102.18
Net Profit 156.23 187.87 234.26 283.71 339.49
Adjusted EPS (Rs.) 20.65 24.79 30.86 37.35 44.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 15.13 15.16 15.18 15.19 15.2
Total Reserves 743.54 915.49 1124.73 1374.96 1685.73
Borrowings 0 0 0 0 0
Other N/C liabilities 24.99 24.63 16.42 13.29 13.7
Current liabilities 77.33 98.88 146.85 118.87 99.85
Total Liabilities 860.99 1054.16 1303.18 1522.31 1814.48
Assets
Net Block 182.68 162.46 156.85 165.79 205.26
Capital WIP 1.36 1.73 42.68 27.75 20.64
Intangible WIP 0 0.87 0 0 0
Investments 138.64 212.73 274.97 346.17 491.11
Loans & Advances 5.67 70.7 164.7 272.07 257.13
Other N/C Assets 20 0 2.28 7.43 14.65
Current Assets 512.64 605.67 661.7 703.1 825.69
Total Assets 860.99 1054.16 1303.18 1522.31 1814.48
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 209.94 250.31 293.15 365.74 441.67
Adjustment 7.75 -19.43 -59.57 -68.57 -84.47
Changes in Assets & Liabilities 131.85 62.07 -11.45 -99.07 -57.49
Tax Paid -54.9 -61.98 -65.03 -87.09 -103.84
Operating Cash Flow 294.64 230.97 157.1 111.01 195.87
Investing Cash Flow -3.9 -276.02 -85.67 -118.13 -138.77
Financing Cash Flow -3.47 -22.76 -30.42 -34.26 -38.1
Net Cash Flow 287.27 -67.81 41.01 -41.38 19

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 70.56 70.57 70.57 70.57 70.57
ashok gorkey partheeban 11.91 11.91 11.91 11.91 11.91
first dimension holdings ... 0.49 0.49 0.49 0.49 0.49
kiraviz properties and co... 0.20 0.20 0.20 0.20 0.20
may india property privat... 2.79 2.79 2.79 2.79 2.79
p vijayalakshmi 24.71 24.71 24.71 24.71 24.71
paarthipan c c 18.64 18.64 18.64 18.64 18.64
partheeban vivek siddarth... 11.84 11.85 11.85 11.85 11.85
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 29.44 29.43 29.43 29.43 29.43
investor education and pr... - 2.71 3.11 3.04 2.87
pinebridge global funds -... - - - 1.05 1.05
uti multi cap fund 1.49 1.55 1.77 1.85 1.81
llp 0.53 - 0.50 - -
investor education and pr... 2.73 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research HDFC Securities
Research HDFC Securities
Research Ventura

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q3FY24
Concall Q3FY21
Concall Q3FY19
Concall Q2FY24
Concall Q2FY24
Concall Q2FY21
Concall Q1FY24
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY20
Presentation Q3FY26
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q2FY20
Presentation Q1FY24
Presentation Q1FY21

Company News

Caplin Point Labs. - Quaterly Results 13 Aug, 12:00 AM Caplin Point Laboratories’ arm gets USFDA approval for Foscarnet Sodium injection 15 May, 10:08 AM Caplin Point Lab - Quaterly Results 15 May, 12:00 AM Caplin Point Laboratories informs about outcome of board meeting 14 May, 4:47 PM Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection 5 May, 3:24 PM Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection 5 May, 3:12 PM Caplin Point’s arm gets USFDA’s final nod for Potassium Phosphates Injection 13 Mar, 2:27 PM Caplin Point Laboratories informs about press release 13 Mar, 12:20 PM Caplin Point’s arm secures USFDA’s final approval for Desmopressin Acetate Injection 2 Mar, 10:07 AM Caplin Point Laboratories informs about press release 24 Feb, 3:25 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Sodium Phosphates Injection 24 Feb, 12:58 PM Caplin Point Lab - Quaterly Results 6 Feb, 12:00 AM Caplin Point’s arm gets USFDA’s nod for Methylprednisolone Acetate Injectable Suspension 27 Jan, 6:02 PM Caplin Point Laboratories informs about board meeting 27 Jan, 5:28 PM Caplin Point Laboratories informs about press release 1 Jan, 12:47 PM Caplin Point Laboratories informs about press release 9 Dec, 5:36 PM Caplin Point Laboratories’ arm gets USFDA’s nod for Linezolid Injection 9 Dec, 3:28 PM Caplin Point Laboratories’ arm gets USFDA’s final approval for Acetaminophen Injection 8 Dec, 4:15 PM Caplin Point Lab - Quaterly Results 6 Nov, 12:00 AM Caplin Point Laboratories informs about un-audited financial results 5 Nov, 4:21 PM Caplin Point’s arm gets USFDA’s approval for Nicardipine Hydrochloride in Sodium Chloride Injection 23 Oct, 4:42 PM Caplin Point Laboratories informs about compliances certificate 4 Oct, 3:34 PM Caplin Point’s arm gets USFDA’s final nod for Milrinone Lactate in 5% Dextrose Injection 3 Sep, 4:14 PM Caplin Point Laboratories informs about press release 3 Sep, 3:42 PM Caplin Point Laboratories reports 23% rise in Q1 consolidated net profit 7 Aug, 3:36 PM Caplin Point Lab - Quaterly Results 7 Aug, 12:54 PM Caplin Point Lab - Quaterly Results 7 Aug, 12:54 PM Caplin Point Lab - Quaterly Results 7 Aug, 12:54 PM Caplin Point Laboratories informs about analyst meet 30 Jul, 2:45 PM Caplin Point Laboratories’ arm executes SPA to acquire entire stake in Triwin Pharma 4 Jun, 3:41 PM Caplin Point Lab - Quaterly Results 15 May, 1:42 PM Caplin Point Lab - Quaterly Results 15 May, 1:42 PM Caplin Point Lab - Quaterly Results 15 May, 1:42 PM Caplin Point’s arm gets USFDA’s final nod for Haloperidol Decanoate Injection 14 May, 2:28 PM Caplin Point Laboratories informs about financial results 7 May, 5:11 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Phytonadione Injectable Emulsion 23 Apr, 3:18 PM Caplin Point Laboratories informs about press release 23 Apr, 12:31 PM Caplin Point Laboratories’ arm acquires Neoethicals Chile SpA 2 Apr, 5:05 PM Caplin Point’s arm gets USFDA’s final nod for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution 27 Feb, 9:37 AM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Laboratories informs about press release 5 Feb, 2:50 PM Caplin Point’s arm gets USFDA’s approval for Procainamide Hydrochloride Injection 5 Feb, 12:20 PM Caplin Point’s arm gets USFDA’s approval for Levetiracetam in Sodium Chloride Injection, infusion bags 17 Jan, 2:28 PM Caplin Point Laboratories receives EIR from USFDA 7 Jan, 10:59 AM Caplin Point Laboratories informs about press release 16 Dec, 5:22 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Difluprednate Ophthalmic Emulsion 16 Dec, 12:48 PM Caplin Point Laboratories informs about loss of share certificate 12 Dec, 2:37 PM Caplin Point Laboratories informs about loss of share certificate 15 Nov, 4:54 PM

Caplin Point Labs. Stock Price Analysis and Quick Research Report. Is Caplin Point Labs. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Caplin Point Labs.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Caplin Point Labs. has a PE ratio of 45.8098069965122 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Caplin Point Labs. has ROA of 20.3483% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Caplin Point Labs. has a Current ratio of 8.2693.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Caplin Point Labs. has a ROE of 22.2091%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Caplin Point Labs. has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Caplin Point Labs. has reported revenue growth of 20.3683% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Caplin Point Labs. for the current financial year is 44.1208915352002%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Caplin Point Labs. is Rs 6 and the yield is 0.1578%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Caplin Point Labs. is Rs 55.2218. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Caplin Point Labs. in Ticker for free. Also, one can get the intrinsic value of Caplin Point Labs. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Caplin Point Labs. FAQs

Q1. What is Caplin Point Labs. share price today?
Ans: The current share price of Caplin Point Labs. is Rs 2529.7.

Q2. What is the market capitalisation of Caplin Point Labs.?
Ans: Caplin Point Labs. has a market capitalisation of Rs 19228.67873712 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Caplin Point Labs.?
Ans: The PE ratio of Caplin Point Labs. is 45.8098069965122 and the P/B ratio of Caplin Point Labs. is 8.85753951788962, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Caplin Point Labs. share?
Ans: The 52-week high share price of Caplin Point Labs. is Rs 2699, and the 52-week low share price of Caplin Point Labs. is Rs 1500.3.

Q5. Does Caplin Point Labs. pay dividends?
Ans: Currently, Caplin Point Labs. pays dividends. Dividend yield of Caplin Point Labs. is around 0.1578%.

Q6. What are the face value and book value of Caplin Point Labs. shares?
Ans: The face value of Caplin Point Labs. shares is Rs 2, while the book value per share of Caplin Point Labs. is around Rs 285.5985. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Caplin Point Labs.?
Ans: Caplin Point Labs. has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Caplin Point Labs.?
Ans: The ROE of Caplin Point Labs. is 22.2091% and ROCE of Caplin Point Labs. is 28.5848%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Caplin Point Labs. a good buy for the long term?
Ans: The Caplin Point Labs. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Caplin Point Labs. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Caplin Point Labs. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Caplin Point Labs.’s financials?
Ans: You can review Caplin Point Labs.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Caplin Point Labs.
X